Drugnews

Updated

Alzheimer’s disease: Asian pipelines and global competitors

As of 2026-11-14, Eisai has an approved lecanemab product and an active Phase 2 E2814 trial, while GemVax’s global Phase 2 GV1001 trial is completed. Global comparators include Lilly’s donanemab and Biogen’s investigational tau antisense therapy diranersen. The table separates mechanisms and development status without ranking efficacy across trials.

Aβ and tau pathways

Focus: disease-modifying therapies. Jurisdictions and trial populations are separated; symptomatic medicines are not exhaustively covered.

Asian companies

AssetCompanyMechanism / routeStageIndicationTrial IDLatest verified recordSources
lecanemab / LEQEMBI
Eisai / Biogen
Anti-Aβ protofibril antibody
IV / SC
Approved; SC pen also approved in Japan
Early Alzheimer’s disease
—
Announced planned five-year follow-up presentations at November CTAD; the conference has not yet occurred.
GV1001
GemVax (South Korea)
Investigational peptide mimicking extra-telomeric hTERT functions
SC
Global Phase 2 completed; not approved
Mild-to-moderate Alzheimer’s disease
NCT05189210 is completed. The company webpage still says ongoing; this table uses the registry status.
E2814
Eisai
Anti-tau antibody with lecanemab
IV; with lecanemab
Phase 2; active, not recruiting
Early Alzheimer’s disease
NCT06602258 is active, not recruiting; confirmatory efficacy has not been established.

Global comparators

AssetCompanyMechanism / routeStageIndicationLatest verified recordSources
donanemab / Kisunla
Eli Lilly
Anti-amyloid antibody
IV
Approved; indications vary by jurisdiction
Early symptomatic Alzheimer’s disease
Announced diagnostic and therapeutic research at AAIC; this is not a new indication approval.
diranersen / BIIB080
Biogen / Ionis
Antisense oligonucleotide targeting MAPT mRNA
Intrathecal
Phase 2 data reported; Phase 3 planned
Early Alzheimer’s disease
Ionis lists Phase 3 initiation of diranersen as an anticipated 2027 milestone in its Q3 update; this remains forward-looking.

Events in the last 90 days

2026-08-17 – 2026-11-14

Sources and downloads

  1. Eisai CTAD announcement — 2026-10-29
  2. LEQEMBI Pen Japan approval — 2026-09-16
  3. GV1001 global Phase 2 registry — 2025-09-04
  4. GemVax expanded access page — Undated
  5. E2814 Phase 2 registry — 2026-02-11
  6. E2814 study protocol synopsis — Undated
  7. Lilly AAIC research announcement — 2026-07-09
  8. Ionis Q3 update: anticipated milestones — 2026-11-09
  9. Biogen CELIA data — 2026-07-14
  10. Biogen CELIA patient disposition and intrathecal dosing — Undated

Information cutoff 2026-11-14